Technical Trend Overview and Price Movement
As of 29 Apr 2026, Lupin Ltd. closed at ₹2,302.10, down 0.95% from the previous close of ₹2,324.25. The stock traded within a range of ₹2,260.55 to ₹2,318.00 during the day, remaining close to its 52-week high of ₹2,376.00, while comfortably above its 52-week low of ₹1,774.00. This price action indicates a consolidation phase near the upper end of its annual range, suggesting that while upward momentum has slowed, the stock remains resilient.
The broader technical trend has shifted from bullish to mildly bullish, signalling a tempering of the strong upward momentum seen previously. This subtle change warrants a closer look at the underlying technical indicators to understand the forces at play.
MACD Signals: Divergent Weekly and Monthly Perspectives
The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario for Lupin. On a weekly basis, the MACD is mildly bearish, indicating that short-term momentum may be weakening. This suggests that the recent price declines could continue or that the stock might enter a consolidation phase in the near term.
Conversely, the monthly MACD remains bullish, reflecting a longer-term positive momentum. This divergence between weekly and monthly MACD readings highlights a potential short-term correction within an overall uptrend, a common pattern in healthy market movements.
RSI and Bollinger Bands: Neutral to Mildly Bullish Signals
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory. This indicates that Lupin is neither overbought nor oversold, providing room for price movement in either direction without immediate risk of reversal due to extreme conditions.
Bollinger Bands add further nuance: weekly readings are bullish, suggesting price strength and potential for upward movement within the band range. Monthly Bollinger Bands are mildly bullish, reinforcing the idea of a cautiously optimistic outlook over the medium term.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Moving Averages and KST: Daily Bullish but Weekly and Monthly Bearish Signals
Daily moving averages for Lupin remain bullish, indicating that short-term price momentum is still positive. This suggests that despite the recent dip, the stock’s immediate trend is supportive of further gains or at least stability above key support levels.
However, the Know Sure Thing (KST) indicator, which is a momentum oscillator, shows mildly bearish signals on both weekly and monthly timeframes. This points to a potential slowdown in momentum over the medium term, aligning with the weekly MACD’s cautionary stance.
Dow Theory and On-Balance Volume (OBV): Mixed Technical Landscape
According to Dow Theory, Lupin’s weekly trend is mildly bearish, while the monthly trend remains mildly bullish. This again underscores the divergence between short-term caution and longer-term optimism.
On-Balance Volume (OBV) readings on both weekly and monthly charts show no clear trend, suggesting that volume is not currently confirming either a strong buying or selling pressure. This lack of volume confirmation often precedes a period of consolidation or sideways movement.
Comparative Returns and Market Context
Examining Lupin’s returns relative to the Sensex provides additional context. Over the past week, Lupin’s stock declined by 0.42%, outperforming the Sensex’s sharper fall of 3.01%. Over one month, however, Lupin fell 1.41% while the Sensex gained 4.49%, indicating some short-term underperformance.
Year-to-date, Lupin has delivered a robust 9.00% return, significantly outperforming the Sensex’s negative 9.78%. Over the past year, Lupin’s 9.53% gain contrasts with the Sensex’s 4.15% loss, highlighting the stock’s resilience amid broader market weakness.
Longer-term returns are even more impressive, with Lupin posting a 224.86% gain over three years compared to the Sensex’s 25.81%, and a 118.41% gain over five years versus the Sensex’s 54.60%. Even over ten years, Lupin’s 45.97% return, while trailing the Sensex’s 200.30%, reflects steady growth in a competitive sector.
Get the full story on Lupin Ltd.! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Mojo Score and Grade Upgrade Reflect Confidence
Lupin’s MarketsMOJO score stands at a strong 81.0, reflecting a favourable assessment across multiple parameters. This score supports the recent upgrade in its Mojo Grade from Buy to Strong Buy, effective 27 Apr 2026. The upgrade signals increased confidence in Lupin’s prospects, driven by its solid fundamentals, technical resilience, and sector positioning.
As a mid-cap stock in the Pharmaceuticals & Biotechnology sector, Lupin’s improved rating suggests it is well placed to capitalise on industry growth trends, despite the current technical caution on shorter timeframes.
Investor Takeaway: Balancing Caution with Opportunity
Investors should note the mixed technical signals for Lupin Ltd. The mildly bearish weekly MACD and KST indicators, alongside neutral RSI and volume trends, suggest a period of consolidation or moderate correction may be underway. However, the bullish monthly MACD, Bollinger Bands, and daily moving averages indicate that the longer-term uptrend remains intact.
Given Lupin’s strong relative performance against the Sensex over the medium to long term, and its recent Mojo Grade upgrade, the stock appears to offer a compelling risk-reward profile for investors with a medium to long-term horizon. Short-term traders may wish to exercise caution and monitor key support levels near ₹2,260 and resistance around the 52-week high of ₹2,376.
Overall, Lupin’s technical momentum shift from bullish to mildly bullish reflects a natural market rhythm, balancing profit-taking and accumulation phases. The stock’s robust fundamentals and sector outlook continue to underpin its appeal in the Pharmaceuticals & Biotechnology space.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
